Brief: Daré Bioscience Announces Publication Of Data From Phase 1 Clinical Trial That Support The Potential Of Dare-Hrt1 Intravaginal Ring As A New Menopausal Hormone Therapy

Dare Bioscience

18/04/2023 13:02

April 18 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES PUBLICATION OF POSITIVE SAFETY
AND
ACCEPTABILITY DATA FROM PHASE 1 CLINICAL TRIAL THAT SUPPORT THE
POTENTIAL OF DARE-HRT1 INTRAVAGINAL RING AS A NEW MENOPAUSAL
HORMONE THERAPY
    * DARÉ BIOSCIENCE ANNOUNCES PUBLICATION OF POSITIVE SAFETY
AND
ACCEPTABILITY DATA FROM PHASE 1 CLINICAL TRIAL THAT SUPPORT THE
POTENTIAL OF DARE-HRT1 INTRAVAGINAL RING AS A NEW MENOPAUSAL
HORMONE THERAPY
    * DARE BIOSCIENCE INC - DARÉ PLANS TO ADVANCE DARE-HRT1 INTO
SINGLE PHASE 3 EFFICACY TRIAL FOR TREATMENT OF VASOMOTOR
SYMPTOMS DUE TO MENOPAUSE
    * DARE BIOSCIENCE - DARE-HRT1 HAS POTENTIAL TO BE FIRST
FDA-APPROVED MONTHLY INTRAVAGINAL RING DELIVERING BOTH ESTROGEN
AND PROGESTOGEN HORMONE THERAPY
    * DARE BIOSCIENCE INC - DARE-HRT1 WAS WELL-TOLERATED AND
HIGHLY
ACCEPTABLE FOR MAJORITY OF WOMEN IN BOTH IVR TREATMENT GROUPS

Source text for Eikon:  ID:nGNX9Kw9G2 
Further company coverage:  DARE.O